Volatility is plaguing Wall Street in light of President Donald Trump's tariffs.
Given that CVS Health's restructuring plan is described as enterprise-wide and ongoing, it is reasonable to expect significant charges in the fourth quarter.
CVS Health (CVS) closed the most recent trading day at $56.82, moving -0.14% from the previous trading session.
CVS Health stock has moved from one of the worst performers in the S&P 500 index in 2024 to the second-best performer this year. It has risen in the last six consecutive weeks and is hovering at its highest level since December 2.
Healthcare stocks are cheap. Earnings are expected to grow solidly, and RFK Jr. won't change that.
CVS Health (CVS 2.01%) is a big name in healthcare, and it has generally been seen as a good way to invest in the industry. In addition to its pharmacy retail operations, the company has a pharmacy benefits management business.
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
Today's stock market has brought about a set of distracting indicators and methods to analyze a potential trade—or investment—opportunity, some of which might be accurate in a completely binary setting. What most investors fail to realize is that all of these indicators and methods rely on price action, which is why today's list cuts down all the noise to focus on one indicator alone.
In the latest trading session, CVS Health (CVS) closed at $54.55, marking a +1.36% move from the previous day.
Investing in pharmacy chains hasn't been a good move in recent years. Rite Aid filed for (and emerged from) bankruptcy, and while its larger rivals aren't in as dire shape, they aren't exactly flourishing.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
CVS Health's poor 2024 performance was driven by negative macro and micro factors. Investors became too pessimistic about the company's forward prospects. A new CEO is a catalyst. Despite weak 2024 financial results, CVS is likely to begin to rebound in 2025. The company remains free cash flow positive, despite myriad challenges.